These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27561199)

  • 1. Synthesis of (125) I-lamivudine and (125) I-lamivudine-ursodeoxycholic acid codrug.
    Motaleb MA; Abo-Kul M; Ibrahim SM; Saad SM; Arafat M
    J Labelled Comp Radiopharm; 2016 Sep; 59(11):451-3. PubMed ID: 27561199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver.
    Chimalakonda KC; Agarwal HK; Kumar A; Parang K; Mehvar R
    Bioconjug Chem; 2007; 18(6):2097-108. PubMed ID: 17922546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid.
    He XL; Wang LT; Gu XZ; Xiao JX; Qiu WW
    Steroids; 2018 Dec; 140():173-178. PubMed ID: 30389306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-continuous multi-step synthesis of lamivudine.
    Mandala D; Chada S; Watts P
    Org Biomol Chem; 2017 Apr; 15(16):3444-3454. PubMed ID: 28362445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, enantiopure synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives as a bioisostere of lamivudine.
    Kim KR; Park AY; Moon HR; Chun MW; Jeong LS
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):911-5. PubMed ID: 18058507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient asymmetric synthesis of lamivudine via enzymatic dynamic kinetic resolution.
    Hu L; Schaufelberger F; Zhang Y; Ramström O
    Chem Commun (Camb); 2013 Nov; 49(88):10376-8. PubMed ID: 24071972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, stability and pharmacological evaluation of a novel codrug consisting of lamivudine and ursolic acid.
    Zhong Y; Dai Z; Xu Y; Teng Y; Wu B
    Eur J Pharm Sci; 2012 Jan; 45(1-2):110-5. PubMed ID: 22085635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
    Anastasi C; Hantz O; De Clercq E; Pannecouque C; Clayette P; Dereuddre-Bosquet N; Dormont D; Gondois-Rey F; Hirsch I; Kraus JL
    J Med Chem; 2004 Feb; 47(5):1183-92. PubMed ID: 14971898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthesis and antiviral activities of geldanamycin analog TC-GM in vitro].
    Li CX; Shan GZ; Fan B; Tao PZ; Zhao LX; Jiang JD; Li YH; Li ZR
    Yao Xue Xue Bao; 2011 Jun; 46(6):683-7. PubMed ID: 21882529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Stereoselective Synthesis of Lamivudine (3TC) and Emtricitabine (FTC) by a Novel N-Glycosidation Procedure.
    Caso MF; D'Alonzo D; D'Errico S; Palumbo G; Guaragna A
    Org Lett; 2015 Jun; 17(11):2626-9. PubMed ID: 25965958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of ursodeoxycholic acid from plant-source (20S)-21-hydroxy-20-methylpregn-4-en-3-one.
    Wang J; Gu XZ; He LM; Li CC; Qiu WW
    Steroids; 2020 May; 157():108600. PubMed ID: 32068080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
    Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
    Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection.
    Kansu A; Doğanci T; Akman SA; Artan R; Kuyucu N; Kalayci AG; Dikici B; Dalgiç B; Selimoğlu A; Kasirga E; Ozkan TB; Kuloğlu Z; Aydoğdu S; Boşnak M; Ertekin V; Tanir G; Haspolat K; Girgin N; Yağci RV
    Antivir Ther; 2006; 11(2):255-61. PubMed ID: 16640106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro evaluation on the effects of combined lamivudine (3TC) and Ara-AMP against hepatitis B virus].
    Su H; Wang H; Ji W; Zhao Y; Cai G
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Mar; 16(1):16-9. PubMed ID: 11986737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.